Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arcturus Therapeutics Holdings Inc ARCT

Healthcare Biotechnology
Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid... see more

Recent & Breaking News (NDAQ:ARCT)

Arcturus Therapeutics to Present at the JMP Securities Life Sciences Conference

GlobeNewswire June 18, 2018

Arcturus Announces Management Appointments; Company Founder Joseph E. Payne Reinstated as President and CEO

GlobeNewswire May 31, 2018

Arcturus Therapeutics Announces Extraordinary General Meeting of Shareholders

GlobeNewswire May 30, 2018

Arcturus Therapeutics Appoints Four New Directors and Reaches Settlement Agreement with Founder Joseph E. Payne

GlobeNewswire May 29, 2018

Arcturus Therapeutics Comments on Court Ruling on Undisclosed Group Organized by Joseph E. Payne and his Associates in Violation of Regulation 13D

GlobeNewswire May 23, 2018

Arcturus Therapeutics Founder Joseph Payne Calls for an End to Company’s Frivolous and Costly Lawsuits; Applauds Court Decision and Welcomes June 25, 2018 EGM Date

GlobeNewswire May 23, 2018

Arcturus Therapeutics Files Form 20-F

GlobeNewswire May 14, 2018

Arcturus Therapeutics Founder Joseph Payne Welcomes Court Decision to Set Date and Agenda of Extraordinary General Meeting to Vote for New Board Members

GlobeNewswire May 14, 2018

Arcturus Therapeutics Founder Joseph Payne Successfully Prevents Board’s Egregious Attempt to Dilute Shareholders

GlobeNewswire May 2, 2018

Arcturus Therapeutics Files Lawsuit Against Joseph E. Payne and His Associates for Violations of Federal Securities Laws

GlobeNewswire April 20, 2018

Arcturus Therapeutics Founder Joseph Payne Disappointed by Board’s Desperate Attempt to Delay Meeting and Avoid Shareholder Accountability

GlobeNewswire April 13, 2018

Arcturus Therapeutics Issues Statement Regarding Timing of Extraordinary General Meeting of Shareholders

GlobeNewswire April 8, 2018

Arcturus Therapeutics Issues Open Letter to Shareholders

GlobeNewswire March 28, 2018

Arcturus Therapeutics Initiates Lawsuit Against Joseph E. Payne to Protect the Interests of Arcturus Shareholders

GlobeNewswire March 27, 2018

Arcturus Therapeutics Calls on Proposed Director Nominees to Respond to Constructive Board Outreach

GlobeNewswire March 5, 2018

The Market In 5 Minutes: GDP, Oil, Parscale, And Baidu's iQiyi

Benzinga.com  February 28, 2018

Arcturus Therapeutics Issues Statement Regarding Extraordinary General Meeting of Shareholders

GlobeNewswire February 26, 2018

Arcturus Therapeutics Comments on Amended 13D Filing

GlobeNewswire February 16, 2018

Arcturus Therapeutics Issues Statement

GlobeNewswire February 6, 2018

Arcturus Therapeutics Appoints Mark Herbert as Interim President

GlobeNewswire February 2, 2018